Tiziana Life Sciences LTD
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Tiziana Life Sciences LTD
RECRUITINGPhase 2NCT06890923
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary...
Sponsor: Tiziana Life Sciences LTDEnrolling: 551 location
Non-Active Secondary Progressive Multiple Sclerosis
RECRUITINGPhase 2NCT06292923
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Foralumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases. The goal of this Phase 2a, randomized, double-blind...
Sponsor: Tiziana Life Sciences LTDEnrolling: 547 locations
Secondary Progressive Multiple Sclerosis